Home    Contact    Sitemap    Search    
  Print page    
  

News archive

2012   2011   2010   2009   2008   2007   2006   2005   2004   

2012.02.02   Photocure’s partner Ipsen announces 4Q 11 Hexvix® sales in Germany and Italy  [Stock Exchange Notice]
2012.01.13   Photocure announces completion of Visonac® study enrolment  [Stock Exchange Notice]
2012.01.09   Photocure ASA - Photocure strengthens the Management Team  [Stock Exchange Notice]
2012.01.03   Photocure ASA - Cevira Study completes study enrolment on time  [Stock Exchange Notice]
2011.12.30   Photocure ASA: Photocure Announces Transfer of Marketing Authorisation for Cysview in the USA  [Stock Exchange Notice]
2011.12.06   DnB Nor Nordic Health Care Conference 2011  
2011.12.05   Photocure - repurchase program of own shares  [Press Release][Stock Exchange Notice]
2011.12.05   Photocure presenting at Nordic health care conference 2011  [Press Release][Stock Exchange Notice]
2011.11.29   Photocure appoints interim Chief Financial Officer  [Press Release][Stock Exchange Notice]
2011.11.28   Photocure nominates market maker on oslo stock exchange  [Press Release][Stock Exchange Notice]
2011.11.18   Photocure announces resignment of Chief Financial Officer  [Press Release][Stock Exchange Notice]
2011.11.07   3rd Quarter Report 2011  [Stock Exchange Notice]
2011.10.24   Invitation to a presentation of the 3rd quarter report 2011  [Stock Exchange Notice]
2011.10.14   Photocure announces the achievement of the first transition milestone of Eur 2.0 million for Hexvix®  [Press Release][Stock Exchange Notice]
2011.09.27   Photocure announces new commercial strategy for Hexvix®, the innovative product for improved detection of bladder cancer  [Stock Exchange Notice]
2011.08.22   From NBC - Cysview and cancer detection  [Stock Exchange Notice]
2011.08.18   Presentation of the 2nd Quarter results 2011  [Stock Exchange Notice]
2011.07.18   Photocure initiates enrollment into phase II trial of Visonac® for treatment of moderate to severe acne  [Stock Exchange Notice]
2011.06.22   Photocure Launches Allumera® A New, Dynamic Cosmetic For Achieving Timeless Skin  [Press Release][Stock Exchange Notice]
2011.06.22   Photocure initiates enrollment into phase II trial of Cevira® for cervical HPV infection  [Press Release][Stock Exchange Notice]
2011.05.30   Photocure Announces First Commercial Sale of Allumera® in the US  [Press Release][Stock Exchange Notice]
2011.05.12   Hexvix®/Cysview(TM) demonstrates long term benefit  [Stock Exchange Notice]
2011.05.12   Photocure Strengthens the Management Team  [Press Release][Stock Exchange Notice]
2011.05.12   Photocure Announces Key Changes to the Board of Directors  [Press Release][Stock Exchange Notice]
2011.04.28   1st Quarter result presentation  
2011.04.26   Presentation of the 1st Quarter 2011 Report  [Press Release][Stock Exchange Notice]
2011.04.05   Notice of annual general meeting  [Stock Exchange Notice]
2011.03.25   Photocure hosts lunch presentation Monday 28 March  
2011.03.23   British Journal of Urology publishes paper on Hexvix®  [Press Release][Stock Exchange Notice]
2011.02.17   Highlights for the fourth quarter and full year 2010  [Stock Exchange Notice]
2011.02.11   Photocure Chairman Erik Engebretsen to resign from the Board of Directors  [Press Release][Stock Exchange Notice]
2011.01.26   Photocure announces successful phase II results for Cevira® Receives FDA approval for studies in US  [Stock Exchange Notice]
2010.11.30   Bladder cancer: Photodynamic diagnosis can improve surgical outcome  
2010.11.29   Photocure announce positive preliminary results from the Allumera(TM) consumer trial  [Stock Exchange Notice]
2010.10.27   3rd Quarter 2010 results from Photocure  [Stock Exchange Notice]
2010.10.20   Photocure signs agreement with Salix Pharmaceuticals for Lumacan(TM)  [Stock Exchange Notice]
2010.10.05   New publication on Hexvix® demonstrating that Hexvix® guided fluorescence cystoscopy reduces recurrence in patients with non-muscle invasive bladder cancer  [Stock Exchange Notice]
2010.10.04   Photocure announces successful Phase II results for Cevira(TM)  [Stock Exchange Notice]
2010.08.19   2nd Quarter results presentation  [Stock Exchange Notice]
2010.08.19   Results for the 2nd quarter and first half year 2010  [Stock Exchange Notice]
2010.08.13   Invitasjon til presentasjon av resultater andre kvartal 2010  [Stock Exchange Notice]
2010.08.04   Photocure establishes US subsidiary to build speciality dermatology business  [Stock Exchange Notice]
2010.05.30   Photocure announces US approval of Cysview(TM) for detection of bladder cancer  [Stock Exchange Notice]
2010.05.28   Photocure announces results from phase II study in acne with Visonac™  [Stock Exchange Notice]
2010.05.26   Feil i regelverket for Innsatsstyrt Finansiering  
2010.05.11   Photocure wins patent case against the US Patent and Trademark Office  [Stock Exchange Notice]
2010.04.28   1st quarter 2010 results  [Stock Exchange Notice]
2010.04.27   Åse Aulie Michelet foreslås som nytt styremedlem i Photocure  [Stock Exchange Notice]
2010.04.26   Presentation of the 1st quarter 2010 report  [Stock Exchange Notice]
2010.04.21   Expert panel recommends the use of Hexvix®-cystoscopy  [Stock Exchange Notice]
2010.04.07   Notice of annual general meeting  [Stock Exchange Notice]
2010.03.29   Annual Report 2009  [Stock Exchange Notice]
2010.03.18   Allotted Share Options  [Stock Exchange Notice]
2010.03.08   Shares purchased by employees and notification of trade  [Stock Exchange Notice]
2010.02.19   Presentation 4th Quarter 2009  [Stock Exchange Notice]
2010.02.19   Results 4th quarter and full year 2009  [Stock Exchange Notice]
2010.02.16   Presentation of the annual report 2009  [Stock Exchange Notice]
2010.01.13   Hexvix® receives reimbursement approval in Germany  [Stock Exchange Notice]
2010.01.06   Inclusion completed in phase II study with Visonac™ for acne  [Stock Exchange Notice]
2010.01.06   Financial calendar 2010  [Stock Exchange Notice]
2009.12.31   Photocure received positive response from FDA on the New Drug Application (NDA) for Hexvix® for detection of bladder cancer  [Stock Exchange Notice]
2009.12.18   FDA Advisory Committee voted favourably to Hexvix® application in USA  [Stock Exchange Notice]
2009.11.26   Photocure granted patent in Europe and Russia for Visonac™ in the treatment of acne  [Stock Exchange Notice]
2009.11.25   Extraordinary General Meeting  [Stock Exchange Notice]
2009.11.23   Shares purchased by employees  [Stock Exchange Notice]
2009.11.20   FDA has posted an Advisory Committee meeting with Photocure to discuss Hexvix® NDA  [Stock Exchange Notice]
2009.11.03   Notice of extraordinary general meeting  [Stock Exchange Notice]
2009.10.28   Capital Markets Day Presentations  [Stock Exchange Notice]
2009.10.28   3rd quarter presentation  [Stock Exchange Notice]
2009.10.28   Share buy back and proposed extraordinary dividend of NOK 4.00/share  [Stock Exchange Notice]
2009.10.27   Information memorandum regarding Photocures divestment of Metvix®  [Stock Exchange Notice]
2009.10.20   Invitation to presentation of 3rd quarter report 2009 and Capital Markets Day  [Stock Exchange Notice]
2009.10.07   Photocure divests Metvix® to Galderma for EUR 51 million  [Stock Exchange Notice]
2009.10.01   Invitation to presentation of Photocure's divestment of Metvix®  [Stock Exchange Notice]
2009.10.01   Presentation of Photocures divestment of Metvix®  [Stock Exchange Notice]
2009.09.29   Market making agreement  [Stock Exchange Notice]
2009.08.31   Hexvix® has been granted priority review by the FDA  [Press Release]
2009.08.14   Presentation 2nd quarter report  [Stock Exchange Notice]
2009.08.10   Presentation of the 2nd quarter 2009 report  [Stock Exchange Notice]
2009.06.30   Photocure submits application for marketing approval for Hexvix® in USA to the FDA  [Stock Exchange Notice]
2009.06.30   Photocure søker markedsføringstillatelse for Hexvix® i USA  [Stock Exchange Notice]
2009.06.26   Improved treatment regimen with Metvix®  
2009.06.11   Hexvix® cystoskopi finner mer kreft og gir mindre tilbakefall  [Stock Exchange Notice]
2009.06.11   Hexvix® cystoscopy detects more cancer and reduces recurrence  [Stock Exchange Notice]
2009.06.10   Photocure presenting at BioEquity Europe 2009 Conference  
2009.05.08   Newly published study reaffirms the efficacy with Metvix®  
2009.04.30   Annual General Meeting  [Stock Exchange Notice]
2009.04.29   Results 1st quarter 2009  [Stock Exchange Notice]
2009.04.21   Metvix® and Aktilite® CL128 approved by Health Canada  [Stock Exchange Notice]
2009.04.17   Notice of Annual General Meeting  [Stock Exchange Notice]
2009.04.17   Presentation of the 1st quarter 2009 report  [Stock Exchange Notice]
2009.04.02   Photocure wins patent case in USA  [Stock Exchange Notice]
2009.04.02   Annual overview  [Stock Exchange Notice]
2009.03.19   Hexvix® reduserer tilbakefall av blærekreft  [Stock Exchange Notice]
2009.03.19   Fluorescence cystoscopy improves detection and resection of papillary bladder cancer lesions and reduces early recurrences  [Stock Exchange Notice]
2009.03.02   Allotted Share Options  [Stock Exchange Notice]
2009.02.27   Results 4th quarter and full year 2008  [Stock Exchange Notice]
2009.02.23   Presentation of the annual report 2008  [Stock Exchange Notice]
2009.02.13   Photocure receives a grant of NOK 4.3 mill from the Norwegian Research Counsel  [Stock Exchange Notice]
2008.12.22   Termination of market maker agreement  [Stock Exchange Notice]
2008.12.17   Updated guidelines confirm high efficacy of topical PDT  
2008.12.15   Financial Calendar 2009  [Stock Exchange Notice]
2008.11.17   Photocures Cevira™ shows positive interim results for treatment of precancerous lesions of the cervix  [Stock Exchange Notice]
2008.10.27   Real-life study confirms that Metvix®-PDT is a cost-effective treatment  
2008.10.24   Third Quarter Report 2008  [Stock Exchange Notice]
2008.10.20   Presentation of the 3rd Quarter 2008 report  [Stock Exchange Notice]
2008.09.12   Phase III study results demonstrate that Hexvix cystoscopy leads to significantly improved patient outcome  [Stock Exchange Notice]
2008.09.09   Photocures newly developed Aktilite® CL512 lamp has received CE mark  [Stock Exchange Notice]
2008.09.08   National Health Service (NHS) in UK commits to adopting photodynamic diagnosis of bladder cancer as a standard procedure  [Stock Exchange Notice]
2008.08.27   Postive Phase II Results with Visonac™ for acne  [Stock Exchange Notice]
2008.08.21   Metvix® prevents pre-cancerous lesions in transplant patients  [Stock Exchange Notice]
2008.08.15   Second Quarter/First Half Report 2008  [Stock Exchange Notice]
2008.08.13   Presentation of the 2nd quarter 2008 report  [Stock Exchange Notice]
2008.07.01   Increase in the tariff for private specialists in Norway  
2008.06.27   Metvixia™ and Aktilite® CL128 approved by FDA  [Stock Exchange Notice]
2008.06.17   Photocure ex. PCI Biotech Holding today  [Stock Exchange Notice]
2008.06.16   Demerger PCI Biotech  [Stock Exchange Notice]
2008.06.10   PCI Biotech raises NOK 60 million in offering  [Stock Exchange Notice]
2008.05.28   Last day including priority  [Stock Exchange Notice]
2008.05.27   The shareholders' meeting in PCI Biotech Holding ASA has passed planned resolutions as preparations for the completion of the demerger of Photocure  [Stock Exchange Notice]
2008.05.22   Metvix® PDT receives full reimbursement in Sweden  [Stock Exchange Notice]
2008.05.21   Excellent clinical trial data from Photocure's photodynamic diagnostic Lumacan(TM)  [Stock Exchange Notice]
2008.05.05   Reimbursement for Metvix® in Iceland  
2008.04.29   Annual information  [Stock Exchange Notice]
2008.04.28   New European Guidelines on bladder cancer in 2008  
2008.04.23   1st Quarter report 2008  [Stock Exchange Notice]
2008.04.21   Presentation of results 1st quarter 2008  [Stock Exchange Notice]
2008.04.10   Annual General Meeting  [Stock Exchange Notice]
2008.04.04   Photocure receives grant of MNOK 9.1 from the Research Council of Norway  [Stock Exchange Notice]
2008.03.30   Mandatory Notification Of Trade  [Stock Exchange Notice]
2008.03.19   Notice of general assembly  [Stock Exchange Notice]
2008.03.14   Preventive effect of Metvix® presented at The EuroPDT Congress in Barcelona  
2008.03.06   Distribution of Demerger documents Photocure - PCI Biotech  [Stock Exchange Notice]
2008.02.29   Allotted Share Options  [Stock Exchange Notice]
2008.02.28   Demerger of PCI Biotech AS  [Stock Exchange Notice]
2008.02.28   Results 2007  [Stock Exchange Notice]
2008.02.26   Photocure - Invitation to the 2007 Financial Results  [Stock Exchange Notice]
2008.02.19   Photocure ASA - Financial Calendar 2008  [Stock Exchange Notice]
2008.02.12   Photocure's new photodynamic diagnostic product shows early promise in detecting premalignant/malignant lesions in patients with suspected colorectal cancer  [Stock Exchange Notice]
2008.02.01   PCI Biotech strengthens the management team  [Stock Exchange Notice]
2007.11.16   Photocure announces plans to de-merge PCI Biotech  [Stock Exchange Notice]
2007.11.05   New patent on Hexvix granted in US  [Stock Exchange Notice]
2007.10.26   Results Third Quarter 2007  [Stock Exchange Notice]
2007.10.23   Presentation of Results 3rd Quarter 2007  [Stock Exchange Notice]
2007.10.16   Positive review of Hexvix® in Nature Clinical Practise  [Stock Exchange Notice]
2007.10.12   Photodynamic Therapy of skin cancer attracts high interest at World Congress of Dermatology  [Stock Exchange Notice]
2007.09.24   Market making agreement  [Stock Exchange Notice]
2007.09.19   GE Healthcare Hexvix symposium during the SIU congress in Paris  [Stock Exchange Notice]
2007.08.24   Employee Share Options Exercised  [Stock Exchange Notice]
2007.08.16   Results Second Quarter 2007  [Stock Exchange Notice]
2007.08.14   Presentation of results 2nd quarter 2007  [Stock Exchange Notice]
2007.08.10   Blue light method cost-effective for health care services  [Stock Exchange Notice]
2007.06.28   Photocure - Metvixia(TM) NDA submitted to FDA  [Stock Exchange Notice]
2007.06.19   Approval for Hexvix obtained in Italy  [Stock Exchange Notice]
2007.06.05   Presentations Capital Markets Day  [Stock Exchange Notice]
2007.06.04   Program Capital Markets Day  [Stock Exchange Notice]
2007.05.30   Price approval and reimbursement for Hexvix obtained in France  [Stock Exchange Notice]
2007.05.03   Invitation to Capital Markets Day  [Stock Exchange Notice]
2007.04.27   Annual General Meeting 2007  [Stock Exchange Notice]
2007.04.25   First quarter results 2007  [Stock Exchange Notice]
2007.04.24   Presentation of first quarter 2007  [Stock Exchange Notice]
2007.04.16   Notice of Annual General Meeting  [Stock Exchange Notice]
2007.03.22   Positive clinical results in patients with suspicion of colorectal cancer  [Stock Exchange Notice]
2007.03.19   PCI Biotech file patents for combination of siRNA and the PCI technology  [Stock Exchange Notice]
2007.03.19   New Agreement Signed with the Norwegian Radium Hospital Research Foundation  [Stock Exchange Notice]
2007.03.14   Employee Share Options Excercised  [Stock Exchange Notice]
2007.03.02   Allotted Share Options  [Stock Exchange Notice]
2007.02.28   Fourth quarter report 2006  [Stock Exchange Notice]
2007.02.22   Invitation to the 2006 Financial Results  [Stock Exchange Notice]
2007.02.14   Two phase III studies on Metvix® PDT/Aktilite® finalised  [Stock Exchange Notice]
2007.01.17   PCI Biotech receives grant of MNOK 8.5 from the NRC  [Stock Exchange Notice]
2007.01.16   Financial Calendar 2007  [Stock Exchange Notice]
2007.01.05   PDT recommended as first line treatment  [Stock Exchange Notice]
2006.12.22   Photocure developing acne treatment independently  [Stock Exchange Notice]
2006.10.27   Third Quarter Report 2006  [Stock Exchange Notice]
2006.10.24   Presentation of 3rd quarter  [Stock Exchange Notice]
2006.09.29   First phase II acne study finalised  [Stock Exchange Notice]
2006.09.04   Employee Share Options Excercised  [Stock Exchange Notice]
2006.08.18   Acne study published in the British Journal of Dermatology  [Stock Exchange Notice]
2006.08.15   Second Quarter Report 2006  [Stock Exchange Notice]
2006.08.09   Presentation of Results 2nd Quarter 2006  [Stock Exchange Notice]
2006.07.31   US option for Hexvix exercised by GE Healthcare  [Stock Exchange Notice]
2006.06.14   PhotoCure - Capital Market Days - Presentations  [Stock Exchange Notice]
2006.05.31   DUSA Pharmaceuticals and PhotoCure ASA Settle Patent Disputes  [Stock Exchange Notice]
2006.05.31   PhotoCure - GE Healthcare has 60 days to exercise US option for Hexvix®.  [Stock Exchange Notice]
2006.05.30   Invitation to Capital Markets Day 14 June 2006  [Stock Exchange Notice]
2006.04.21   PhotoCure ASA - Annual General Meeting  [Stock Exchange Notice]
2006.04.20   First Quarter Report 2006  [Stock Exchange Notice]
2006.04.20   FDA requests more information related to Hexvix® NDA  [Stock Exchange Notice]
2006.04.07   PhotoCure and GE Healthcare introduce Hexvix in Europe  [Stock Exchange Notice]
2006.04.07   PhotoCure - Notice of Annual General Meeting  [Stock Exchange Notice]
2006.03.28   PhotoCure - Efficient cancer gene therapy induced by the PCI technology  [Stock Exchange Notice]
2006.03.28   PhotoCure - Employee Share Options Excercised  [Stock Exchange Notice]
2006.03.09   NICE recommends PDT for common skin cancer and pre-malign lesions  [Stock Exchange Notice]
2006.02.28   PhotoCure ASA - Results 2005  [Stock Exchange Notice]
2006.02.21   PhotoCure - Invitation to the 2005 Financial Results  [Stock Exchange Notice]
2006.02.08   Metvix PDT in acne: New study published in British Journal of Dermatology  [Stock Exchange Notice]
2006.02.06   PhotoCure - Subscription period  [Stock Exchange Notice]
2006.01.25   PhotoCure - Extraordinary general meeting 24 January 2006  [Stock Exchange Notice]
2006.01.09   PhotoCure - Licensing deal with GE Healthcare for bladder cancer  [Stock Exchange Notice]
2005.12.05   PCI technology enhances effect of anti-cancer drug  [Stock Exchange Notice]
2005.11.25   Metvix® approved for Bowen's in 22 European countries  [Stock Exchange Notice]
2005.10.28   Third Quarter Results 2005  [Stock Exchange Notice]
2005.10.21   Invitation to Presentation of Third Quarter Results 2005  [Stock Exchange Notice]
2005.09.19   Hexvix recommended for diagnosis of bladder cancer  [Stock Exchange Notice]
2005.09.15   Metvix approved in Brazil  [Stock Exchange Notice]
2005.09.06   Shares in Algeta ASA sold  [Stock Exchange Notice]
2005.08.24   Employee Share Options Excercised  [Stock Exchange Notice]
2005.08.12   Second Quarter Results 2005  [Stock Exchange Notice]
2005.08.05   Invitation to Presentation of Second Quarter Results 2005  [Stock Exchange Notice]
2005.06.30   Hexvix® NDA submitted to FDA  [Stock Exchange Notice]
2005.06.10   First study in acne shows promising results  [Stock Exchange Notice]
2005.05.04   Annual General Meeting  [Stock Exchange Notice]
2005.05.03   First quarter results 2005  [Stock Exchange Notice]
2005.04.28   Presentation of first quarter results 2005  [Stock Exchange Notice]
2005.04.27   Transition to IFRS  [Stock Exchange Notice]
2005.04.20   Notice of general meeting  [Stock Exchange Notice]
2005.04.06   PhotoCure and Galderma free to market Metvix® in Australia  [Stock Exchange Notice]
2005.03.30   Updated Financial Calender 2005  [Stock Exchange Notice]
2005.03.17   Infringement of the disclosure obligation  [Stock Exchange Notice]
2005.03.09   Nomination Committee established  [Stock Exchange Notice]
2005.03.02   Hexvix® approved in 26 European countries  [Stock Exchange Notice]
2005.03.02   PhotoCure ASA - Allotted Share Options  [Stock Exchange Notice]
2005.02.28   Allotted Share Options  [Stock Exchange Notice]
2005.02.24   PhotoCure results 2004  [Stock Exchange Notice]
2005.02.17   Invitation to the 2004 Financial Results  [Stock Exchange Notice]
2004.12.03   FDA Review of Metvix® for the treatment of skin cancer  [Stock Exchange Notice]
2004.12.01   Hexvix® marketing application found fileable in 26 European countries  [Stock Exchange Notice]
2004.11.29   Metvix® approved in 8 new European countries  [Stock Exchange Notice]
2004.11.26   PhotoCure appoints Kjetil Hestdal as new President and CEO  [Stock Exchange Notice]
2004.11.10   PhotoCure strengthens its management team  [Stock Exchange Notice]
2004.10.20   Results third quarter 2004  [Stock Exchange Notice]
2004.10.08   Invitation Presentation 3rd Quarter 2004  [Stock Exchange Notice]
2004.09.23   Hexvix® application in EU / EEA countries to be filed later this year  [Stock Exchange Notice]
2004.09.20   Marketing approval for Hexvix®  [Stock Exchange Notice]
2004.08.20   Results second quarter 2004  [Stock Exchange Notice]
2004.08.18   Agreement to mediate with DUSA  [Stock Exchange Notice]
2004.08.09   Presentation of Results 2nd Quarter 2004  [Stock Exchange Notice]
2004.07.28   Regulatory Approval of Metvix® in the US  [Stock Exchange Notice]
2004.06.17   US New Drug Application approval expected for Metvix  [Stock Exchange Notice]
2004.05.27   Galderma initiates new Metvix® launches  [Stock Exchange Notice]
2004.05.07   Results first quarter 2004  [Stock Exchange Notice]
2004.04.16   Annual General Meeting  [Stock Exchange Notice]
2004.03.26   Notice of General Meeting  [Stock Exchange Notice]
2004.02.27   Allotted Employee Share Options and Share Issue  [Stock Exchange Notice]
2004.02.25   PhotoCure Results 2003  [Stock Exchange Notice]
2003.11.28   PhotoCure Wins Award for Design Excellence  [Stock Exchange Notice]
2003.11.25   Metvix® progresses  [Stock Exchange Notice]
2003.11.06   Third Quarter Results 2003  [Stock Exchange Notice]
2003.10.02   Acknowledged by New Social Responsibility Index (SRI)  [Stock Exchange Notice]
2003.09.25   Hexvix® imaging one step closer to commercialisation  [Stock Exchange Notice]
2003.09.11   FDA Advisory Committee Reviews Metvix® for the treatment of skin cancer  [Stock Exchange Notice]
2003.08.28   PhotoCure awarded Prize for Innovation  [Stock Exchange Notice]
2003.08.20   Employee Share Options Excercised  [Stock Exchange Notice]
2003.08.19   Second Quarter Results 2003  [Stock Exchange Notice]
2003.08.08   Progress in FDA's evaluation of Metvix® application  [Stock Exchange Notice]
2003.08.04   Annual General Meeting  [Stock Exchange Notice]
2003.07.08   Collaboration agreement between PhotoCure and Karl Storz  [Stock Exchange Notice]
2003.06.19   Employee Share Options Excercised  [Stock Exchange Notice]
2003.06.17   New approval for Metvix® in Australia  [Stock Exchange Notice]
2003.06.17   Presentation for Nordic Urologists  [Stock Exchange Notice]
2003.05.13   First Quarter Results 2003  [Stock Exchange Notice]
2003.05.09   Galderma initiates Metvix® PDT UK launch activities  [Stock Exchange Notice]
2003.04.02   Metvix® PDT approved in Australia  [Stock Exchange Notice]
2003.04.02   Positive Metvix® PDT results  [Stock Exchange Notice]
2003.03.28   Hexvix® improves treatment of bladder cancer patients  [Stock Exchange Notice]
2003.03.18   Notice of General Meeting  [Stock Exchange Notice]
2003.02.25   New Agreement Signed with the Norwegian Radium Hospital Research Foundation  [Stock Exchange Notice]
2003.02.25   PhotoCure - Results 2002  [Stock Exchange Notice]
2003.02.24   Marketing Application for Metvix® PDT in Australia Recommended for Approval  [Stock Exchange Notice]
2003.02.18   New NDA for Metvix® PDT Submitted to FDA  [Stock Exchange Notice]
2003.02.17   Presentation of Results 2002  [Stock Exchange Notice]
2003.02.06   Metvix® PDT Launched in Germany  [Stock Exchange Notice]
2003.01.15   Investor Presentation in Copenhagen, Denmark  [Stock Exchange Notice]
2002.12.18   PhotoCure Files First MAA for Hexvix® Cystoscopy  [Stock Exchange Notice]
2002.12.16   PhotoCure - Share Option Plan 2003  [Stock Exchange Notice]
2002.12.10   Change in the Board of Directors  [Stock Exchange Notice]
2002.11.06   Third Quarter Results 2002  [Stock Exchange Notice]
2002.09.23   Metvix® PDT approvable in the US  [Stock Exchange Notice]
2002.09.03   Positive Phase III Clinical Results for Hexvix®  [Stock Exchange Notice]
2002.08.19   High Clinical Acceptance of Metvix®PDT  [Stock Exchange Notice]
2002.06.14   PhotoCure subscribes shares in Anticancer Therapeutic Inventions AS  [Stock Exchange Notice]
2002.06.12   Employee share options exercised  [Stock Exchange Notice]
2002.05.23   National Marketing Authorisation for Metvix® PDT issued in Finland  [Stock Exchange Notice]
2002.05.09   Investor Presentation in Baltimore, US  [Stock Exchange Notice]
2002.05.07   Commercialisation of Metvix®PDT in Europe on track  [Stock Exchange Notice]
2002.05.07   Employee Share Options  [Stock Exchange Notice]
2002.04.12   PhotoCure callenges patent in Australia  [Stock Exchange Notice]
2002.03.21   Notice of General Meeting  [Stock Exchange Notice]
2002.03.21   Annual General Meeting  [Stock Exchange Notice]
2002.03.13   Dispute Resolved at the Norwegian Radium Hospital  [Stock Exchange Notice]
2002.03.06   National Marketing Authorisation for Metvix® PDT issued in Germany  [Stock Exchange Notice]
2002.02.27   Employee share options exercised  [Stock Exchange Notice]
2002.02.27   Report for 2001  [Stock Exchange Notice]
2002.02.11   Long-term Phase III Study with Metvix® for BCC  [Stock Exchange Notice]
2002.02.08   PhotoCure Receives Marketing Approval for Metvix® PDT in New Zealand  [Stock Exchange Notice]
2002.02.02   Employee share options exercised  [Stock Exchange Notice]
2002.01.31   Metvix® PDT approved in Norway  [Stock Exchange Notice]
2002.01.16   Investor Presentation in Copenhagen, Denmark  [Stock Exchange Notice]
2002.01.15   Metvix® application Switzerland  [Stock Exchange Notice]
2002.01.10   Financial Events 2002  [Stock Exchange Notice]


 
  Photocure ASA, Hoffsveien 4, NO-0275 Oslo, Norway. Telephone: +47 22 06 22 10 Fax: +47 22 06 22 18